Opening an autophagy window as the apoptosis door starts to close
(Tokyo Medical and Dental University) Tokyo Medical and Dental University (TMDU) researchers have successfully attached the cancer cell-targeting antibody Trastuzumab to a previously reported supermolecule that induces autophagic cell death. The antibody-drug conjugate (ADC) selectively targeted HER2-overexpressing cancer calls and reduced cell viability at lower concentrations than free supermolecule drug. It is hoped that the ADC will provide a targeted autophagic death route for treating apoptosis resistant cancer cells in vivo, and ultimately provide an alternate approach in the clinic. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 24, 2020 Category: Biology Source Type: news

Abemaciclib Cuts Early Recurrence in High-risk Breast Cancer Abemaciclib Cuts Early Recurrence in High-risk Breast Cancer
Patients with HR+, HER2- breast cancer at high risk of early recurrence on endothelial therapy could highly improve their invasive disease-free survival with adjuvant abemaciclib, a new trial shows.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 21, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

First new drug in years reduces recurrence in high risk HR+ early breast cancer
(European Society for Medical Oncology) Lugano, Switzerland, 20 September 2020 - Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study at ESMO 2020. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 20, 2020 Category: International Medicine & Public Health Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Media News - September 17, 2020 Category: Pharmaceuticals Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Investor Update - September 17, 2020 Category: Pharmaceuticals Source Type: news

New therapy targets breast cancer metastases in brain
(Northwestern University) When breast cancer spreads to the brain, the prognosis is grim. Patients only have about six months to live. Women with HER2-positive breast cancer tend to develop brain metastases in up to 55% of cases. Chemotherapy drugs targeting breast cancer cells in the brain aren't effective, because they can't cross the blood-brain-barrier. But a new combination therapy targeting breast cancer tumors in the brain dramatically decreased tumor size and increased survival in a preclinical study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 26, 2020 Category: Cancer & Oncology Source Type: news

Autologous HER2 CAR T Cells Induce Rhabdomyosarcoma Remission Autologous HER2 CAR T Cells Induce Rhabdomyosarcoma Remission
Infusion of autologous HER2 CAR T cells after lymphodepleting chemotherapy induced remission in a child with metastatic rhabdomyosarcoma (RMS), researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 20, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoi...
Source: Roche Investor Update - August 6, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoi...
Source: Roche Media News - August 6, 2020 Category: Pharmaceuticals Source Type: news

Investigational breast cancer vaccine plus immune therapy work well in tandem
(Duke University Medical Center) A vaccine for HER2-positive breast cancers that is being tested in a clinical trial at Duke Cancer Institute is part of an effective, two-drug strategy for enlisting the immune system to fight tumors, according to a Duke-led study in Clinical Cancer Research, a journal of the American Association for Cancer Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 30, 2020 Category: Cancer & Oncology Source Type: news

FDA approves Roche ’s new VENTANA HER2 Dual ISH test as companion diagnostic to identify breast cancer patients eligible for targeted therapy
Basel, 29 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced US Food and Drug Administration (FDA) approval of the new VENTANA HER2 Dual ISH DNA Probe Cocktail assay for the detection of the HER2 biomarker in breast cancer and as a companion diagnostic for Herceptin (trastuzumab) therapy. HER2 - human epidermal growth factor receptor 2 - is an important biomarker sometimes found in breast cancers.2 Its detection and inhibition can help healthcare professionals more effectively manage this aggressive cancer. The VENTANA HER2 Dual ISH DNA Probe Cocktail assay is designed to be completed within the same day, enabl...
Source: Roche Investor Update - July 29, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s new VENTANA HER2 Dual ISH test as companion diagnostic to identify breast cancer patients eligible for targeted therapy
Basel, 29 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced US Food and Drug Administration (FDA) approval of the new VENTANA HER2 Dual ISH DNA Probe Cocktail assay for the detection of the HER2 biomarker in breast cancer and as a companion diagnostic for Herceptin (trastuzumab) therapy. HER2 - human epidermal growth factor receptor 2 - is an important biomarker sometimes found in breast cancers.2 Its detection and inhibition can help healthcare professionals more effectively manage this aggressive cancer. The VENTANA HER2 Dual ISH DNA Probe Cocktail assay is designed to be completed within the same day, enabl...
Source: Roche Media News - July 29, 2020 Category: Pharmaceuticals Source Type: news

Indigenous American Ancestry Tied to HER2 + Breast Cancer
Higher proportion of Indigenous American ancestry associated with a greater incidence of HER2 + breast cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 28, 2020 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pathology, Journal, Source Type: news

Indigenous American Ancestry Tied to HER2+ Breast Cancer
TUESDAY, July 28, 2020 -- Indigenous American (IA) origin could partly contribute to the higher incidence of human epidermal growth factor receptor 2-positive (HER2+) breast cancer in Latinas, according to a study recently published in Cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 28, 2020 Category: Pharmaceuticals Source Type: news

Indigenous American Ancestry Tied to HER2 & #43; Breast Cancer
TUESDAY, July 28, 2020 -- Indigenous American (IA) origin could partly contribute to the higher incidence of human epidermal growth factor receptor 2-positive (HER2+) breast cancer in Latinas, according to a study recently published in Cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 28, 2020 Category: Pharmaceuticals Source Type: news

New MBC Treatments: Triple-Negative; HER2+; and ER+, HER2- New MBC Treatments: Triple-Negative; HER2+; and ER+, HER2-
The latest therapeutic options improve progression-free survival for some patients.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 16, 2020 Category: Consumer Health News Tags: Hematology-Oncology Article Source Type: news

Immunotherapy with CAR T cells results in exceptional patient recovery
(Baylor College of Medicine) In a clinical trial, a child with rhabdomyosarcoma, a form of muscle cancer, that had spread to the bone marrow, showed no detectable cancer following treatment with chimeric antigen receptor (CAR) T cells that were engineered to target the HER2 protein on the surface of the cancer cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 15, 2020 Category: Cancer & Oncology Source Type: news

FDA Approves At-Home Treatment For HER2-Positive Breast Cancer
Some breast cancer patients may qualify for a newly-approved at-home treatment. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 1, 2020 Category: Pharmaceuticals Authors: Marla Milling, Contributor Tags: Healthcare /healthcare Innovation /innovation Source Type: news

Trastuzumab cost effective in HER2-positive metastatic gastric cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2020 Category: Drugs & Pharmacology Source Type: news

Genentech wins FDA OK for at-home combo of 2 marquee cancer drugs
Genentech Inc. won regulatory approval Monday of a breast cancer treatment that combines Herceptin and Perjeta with an enzyme and can be administered at home. The drug, branded as Phego, is the first time South San Francisco-based Genentech has combined two monoclonal antibodies that can be administered by a single injection just under the skin in combination with intravenous chemotherapy. With the enzyme hyaluronidase, it was approved for treatment of early and metastatic HER2-positive breast cancer. Genentech… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 29, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Genentech wins FDA OK for at-home combo of 2 marquee cancer drugs
Genentech Inc. won regulatory approval Monday of a breast cancer treatment that combines Herceptin and Perjeta with an enzyme and can be administered at home. The drug, branded as Phesgo, is the first time South San Francisco-based Genentech has combined two monoclonal antibodies that can be administered by a single injection just under the skin in combination with intravenous chemotherapy. With the enzyme hyaluronidase, it was approved for treatment of early and metastatic HER2-positive breast… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 29, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

FDA Approves Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) for HER2-Positive Breast Cancer
South San Francisco, CA -- June 29, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Phesgo, a fixed-dose combination (FDC) of Perjeta®... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 29, 2020 Category: Drugs & Pharmacology Source Type: news

FDA approves combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for HER2-positive breast cancer
Hematology / Oncology Approval (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 29, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer
             Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Phesgo ™, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC i...
Source: Roche Media News - June 29, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer
             Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Phesgo ™, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC i...
Source: Roche Investor Update - June 29, 2020 Category: Pharmaceuticals Source Type: news

Early Breast Cancer Highlights From ASCO 2020 Early Breast Cancer Highlights From ASCO 2020
Early breast cancer highlights from ASCO 2020 include refinement of adjuvant regimens in HER2+, selection of patients for chemo in ER+, and large-dose capecitabine maintenance in operable TNBC.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 24, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Highlights in Non-Small Cell Lung Cancer From ASCO 2020 Highlights in Non-Small Cell Lung Cancer From ASCO 2020
Dr Mark Kris reports on key studies in NSCLC from ASCO 2020, including the practice-changing ADAURA trial, results on an antibody-drug conjugate targeting HER2, and data on a new checkpoint inhibitor.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Key Studies in Metastatic Breast Cancer From ASCO 2020 Key Studies in Metastatic Breast Cancer From ASCO 2020
Key studies in metastatic breast cancer from ASCO 2020 focus on first-line checkpoint inhibition in TNBC; also, updated evidence that tucatinib plus chemotherapy benefits women with HER2+ disease.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 22, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Roche ’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints
      ·Phase III IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone compared to current standard-of-care (abiraterone and prednisone/prednisolone alone) plus placebo met its co-primary endpoint of radiographic progression free survival (rPFS) in patients with PTEN loss tumoursBasel, 19 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCR...
Source: Roche Media News - June 19, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer
Basel, 18 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion031 study, evaluating Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel; followed by doxorubicin and cyclophosphamide) in comparison to placebo plus chem otherapy (including Abraxane), met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pathological complete response (pCR) for the treatment of people with early triple-negative breast cancer (TNBC), regardless of PD-L1 expression.“Tripl...
Source: Roche Media News - June 18, 2020 Category: Pharmaceuticals Source Type: news

Tucatinib Combination Induces Positive Intracranial Responses in HER2-Positive Breast Cancer Brain Metastases
Tucatinib in combination with trastuzumab and capecitabine yielded significant intracranial responses in patients with previously treated HER2-positive metastatic breast cancer and brain metastases. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2020 Category: Cancer & Oncology Authors: Lisa Astor Source Type: news

Need HER2+ Testing in CRC; Trastuzumab Deruxtecan Shows Benefit Need HER2+ Testing in CRC; Trastuzumab Deruxtecan Shows Benefit
Durable responses seen in phase 2 trial of trastuzumab deruxtecan in patients with heavily pretreated HER2-positive colorectal cancer suggests that HER2 testing become standard of care, argues expert.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 1, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Ribociclib for HR+/HER2- ABC: cost effective in Canada or USA?
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2020 Category: Drugs & Pharmacology Source Type: news

Tucatinib Improves PFS, OS in HER2+ BC With Brain Metastases Tucatinib Improves PFS, OS in HER2+ BC With Brain Metastases
In HER2-positive breast cancer patients with brain metastases treated with trastuzumab and capecitabine, tucatinib increased median overall survival from 12 months to 18.1 months in a phase 2 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 31, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Targeting HER2 Alterations in Non-Small-Cell Lung Cancer Targeting HER2 Alterations in Non-Small-Cell Lung Cancer
A better understanding of the role of HER2 alterations in non-small cell lung cancer could aid in the development of more targeted therapies.JCO Precision Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 29, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Trastuzumab combined with trimodality treatment does not improve outcomes for patients
(NRG Oncology) Results of the NRG Oncology clinical trial RTOG 1010 indicated that the addition of the monoclonal antibody trastuzumab to neoadjuvant trimodality treatment did not improve disease-free survival (DFS) outcomes for patient with HER2 overexpressing local and locally advanced esophageal adenocarcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 29, 2020 Category: Cancer & Oncology Source Type: news

Trastuzumab achieves slight reduction in recurrence for women with HER2-positive DCIS
(NRG Oncology) The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) on the NRG Oncology clinical trial NSABP B-43. The trial did find a statistically non-significant, modest (19%) reduction in the rate of recurrence among women that received trastuzumab, but this difference was not statistically significant. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 29, 2020 Category: Cancer & Oncology Source Type: news

NICE draft guidance recommends new treatment option for people with early breast cancer
NICE has published draft guidance which recommends trastuzumab emtansine (also called Kadcyla and made by Roche) as an option for some people with HER2-positive early breast cancer. (Source: NHS Networks)
Source: NHS Networks - May 11, 2020 Category: UK Health Source Type: news

Phase I/II Trial To Evaluate Dual HER2 Combination Therapy in HR+, HER2+ Breast Cancer
The multi-center trial is comprised of 2 phases, with phase I determining the maximum tolerated dose of palbociclib and phase II determining the clinical benefit rate of treatment with anastrozole, palbociclib, trastuzumab, and pertuzumab. (Source: CancerNetwork)
Source: CancerNetwork - April 29, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Novel Combo Boosts Response in HER2 – Breast Cancer Novel Combo Boosts Response in HER2 – Breast Cancer
Neoadjuvant therapy with a novel combination of checkpoint inhibitor and PARP inhibitor showed benefit in all HER2-negative tumor subtypes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 28, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Study shows immunotherapy prior to surgery may help destroy high-risk breast cancer
(Yale University) A new study led by Yale Cancer Center (YCC) researchers shows women with high-risk HER2-negative breast cancer treated before surgery with immunotherapy, plus a PARP inhibitor with chemotherapy, have a higher rate of complete eradication of cancer from the breast and lymph nodes compared to chemotherapy alone. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 28, 2020 Category: Cancer & Oncology Source Type: news

Study finds no overall survival benefit, but improved quality of life with talazoparib in advanced BRCA-mutated breast cancer
(University of Texas M. D. Anderson Cancer Center) New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes. Most patients included in the study went on to receive subsequent systemic therapies, which may have affected the survival outcome analysis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 27, 2020 Category: International Medicine & Public Health Source Type: news

Risk of Breast Cancer in Latinas May Be Due to Subtype-Specific Genetic Risk Variants
This study observed a positive association between Indigenous American genetic ancestry and HER2-positive breast cancer, suggesting that the high incidence of HER2-positive subtypes in Latinas may be due to population and subtype-specific genetic risk variants. (Source: CancerNetwork)
Source: CancerNetwork - April 24, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Miracle microbes in the Red Sea? Active compounds from its brinepool microbes have chemotherapeutic effects on certain cancers
(Natural News) Despite advances in modern medicine and personalized medicine, some forms of cancer still exist for which limited treatment options are available. For example, penta-negative tumors, which are negative for estrogen and progesterone receptors, EGFR, HER2 and cytokeratin 5/6, have been reported in Saudi women. Triple-negative breast cancer, an aggressive type of cancer that has... (Source: NaturalNews.com)
Source: NaturalNews.com - April 21, 2020 Category: Consumer Health News Source Type: news

Tukysa Approved for Unresectable, Metastatic HER2-Positive Breast Cancer
Title: Tukysa Approved for Unresectable, Metastatic HER2-Positive Breast CancerCategory: Health NewsCreated: 4/20/2020 12:00:00 AMLast Editorial Review: 4/21/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 21, 2020 Category: Cancer & Oncology Source Type: news

Tukysa Approved for Unresectable, Metastatic HER2-Positive Breast Cancer
MONDAY, April 20, 2020 -- The U.S. Food and Drug Administration announced Friday the approval of Tukysa (tucatinib) in combination with trastuzumab and capecitabine for treatment of advanced unresectable or metastatic human epidermal growth factor... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 20, 2020 Category: General Medicine Source Type: news

TUKYSA (tucatinib), FDA Approved for Treatment of Advanced Unresectable or Metastatic HER2 Positive Breast Cancer, Available at Biologics by McKesson
CARY, N.C., April 20, 2020 —Biologics by McKesson, an independent specialty pharmacy for oncology and other rare and complex therapeutic areas, has been selected by Seattle Genetics as a specialty pharmacy provider for TUKYSATM (tucatinib) for the treatment of HER2 positive breast cancer. (Source: McKesson News)
Source: McKesson News - April 20, 2020 Category: Information Technology Source Type: news

FDA Approves First New Breast Cancer Drug With International Group FDA Approves First New Breast Cancer Drug With International Group
The approval is for the oral therapy tucatinib (Tukysa, Seattle Genetics) for the treatment of advanced HER2-positive breast cancer.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 18, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA approves new drug for patients with metastatic breast cancer
The US Food and Drug Administration has approved the use of the drug tucatinib, or Tukysa, in combination with chemotherapy, for the treatment of adults with advanced forms of HER2-positive breast cancer that either cannot be removed with surgery, or has spread to other parts of the body, including the brain. (Source: CNN.com - Health)
Source: CNN.com - Health - April 18, 2020 Category: Consumer Health News Source Type: news

FDA Approves Tukysa (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer
BOTHELL, Wash.--(BUSINESS WIRE) April 17, 2020 -- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the U.S. Food and Drug Administration (FDA) granted approval to Tukysa™ (tucatinib) tablets in combination with trastuzumab and capecitabine... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 18, 2020 Category: Drugs & Pharmacology Source Type: news